Table 4 Comparison between the two groups with AXL < 30 mm and AXL≧30 mm regarding the changes in median CFT and BCVA (logMAR)
From: Result of intravitreal aflibercept injection for myopic choroidal neovascularization
Parameter | AXL < 30 mm | AXL≧ 30 mm | p a | ||||
|---|---|---|---|---|---|---|---|
Median | IQR [range] | Min-Max | Median | IQR [range] | Min-Max | ||
Change in median CFT (μm) | −32.00 | 59.00 [−64.00- -5.00] | − 109.00-45.00 | −45.50 | 77.75 [−97.75- -20] | − 109- -7.00 | 0.246 |
Change in BCVA (logMAR) | |||||||
Three months after aflibercept injection | − 0.30 | 0.48 [− 0.58- -0.10] | −1.28-0.01 | − 0.48 | 0.51 [− 0.74- -0.23] | − 1.10- -0.1 | 0.276 |
Twelve months after aflibercept injection | − 0.30 | 0.66 [− 0.81- -0.15] | − 1.28-0.16 | − 0.52 | 0.50 [− 0.83- -0.33] | −1.25- -0.10 | 0.274 |